Pharmacological Treatment of Insomnia

  • Paula K. Schweitzer
  • Denise Troy Curry
  • Rhody D. Eisenstein
  • James K. Walsh
Part of the Current Clinical Neurology book series (CCNEU)


Drugs currently used for the treatment of insomnia include benzodiazepine receptor agonists (BzRAs), a melatonin receptor agonist, sedating antidepressants, several atypical antipsychotics, sedating antihistamines, and unregulated substances such as valerian and melatonin. Among these compounds substantial evidence of efficacy exists only for the BzRAs and ramelteon; moreover, these drugs are among the safest of centrally acting drugs in common clinical use. Sufficient variability in BzRA pharmacokinetics provides clinicians with options to meet the needs of most patients. Efficacy and safety data of other drugs used to treat insomnia are currently inadequate to allow evidence-based treatment decisions. As the view of insomnia changes from a symptom of an underlying disorder to that of an independent, often chronic disorder, commonly comorbid with a variety of medical and psychiatric conditions, there is increased recognition of the need for long-term treatment. Further research on long-term use and use in comorbid illness is needed. Improvement in the management of insomnia will result from systematic research with these drugs, with drugs in development, and with novel therapeutic approached, such as combined therapies.


Insomnia Pharmacotherapy Benzodiazepine receptor agonists Melatonin receptor agonists Antidepressants Melatonin Valerian 


  1. 1.
    National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. (2005) Sleep 28:1049–1057Google Scholar
  2. 2.
    Walsh JK, Schweitzer PK (1999) Ten-year trends in the pharmacological treatment of insomnia. Sleep 22:371–375PubMedGoogle Scholar
  3. 3.
    Walsh JK (2004) Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 27(8):1441–1442PubMedGoogle Scholar
  4. 4.
    National Institute of Mental Health (1984) Consensus conference report: drugs and insomnia-the use of medication to promote sleep. JAMA 251:2410–2414CrossRefGoogle Scholar
  5. 5.
    Mendelson WB, Roth T, Cassella J, Roehrs T, Walsh JK, Woods JH et al (2004) The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit (NCDEU) meeting symposium. Sleep Med Rev 8:7–17PubMedCrossRefGoogle Scholar
  6. 6.
    McCall WV (2002) Pharmacologic treatment of insomnia. In: Lee-Chiong TL Jr, Sateia MJ, Carskadon MA (eds) Sleep Medicine. Hanley & Belfus, Inc., Philadelphia, PA, pp 169–176Google Scholar
  7. 7.
    Roehrs T, Roth T (2003) Hypnotics: An update. Current Neurol Neurosci Rep 3:181–184CrossRefGoogle Scholar
  8. 8.
    Ohayon MM (1997) Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiat Res 31:333–346PubMedCrossRefGoogle Scholar
  9. 9.
    Buysse DJ, Reynolds CF III, Kupfer DJ, Thorpy MJ, Bixler E, Manfredi R et al (1994) Clinical diagnoses in 216 insomnia patients using the international classification of sleep disorders (ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH DSM-IV field trial. Sleep 17:630–637PubMedGoogle Scholar
  10. 10.
    Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46:53–58PubMedGoogle Scholar
  11. 11.
    Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997) Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42:209–212PubMedCrossRefGoogle Scholar
  12. 12.
    Agargun MY, Kara H, Solmaz M (1997) Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatr 58:249–251CrossRefGoogle Scholar
  13. 13.
    Hall RC, Platt DE (1999) Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics 40:18–27PubMedCrossRefGoogle Scholar
  14. 14.
    Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MG (1997) Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol 146:105–114PubMedCrossRefGoogle Scholar
  15. 15.
    Breslau N, Roth T, Rosenthal L, Andreski P (1996) Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 39:411–418PubMedCrossRefGoogle Scholar
  16. 16.
    Walsh JK (2008) What medications are used to treat insomnia. Paper presented at Development of Hypnotic Agents, Sleep Research Society, New York, 3–4 April 2008Google Scholar
  17. 17.
    Roehrs T, Hollebeek E, Drake C, Roth T (2002) Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 53:571–576PubMedCrossRefGoogle Scholar
  18. 18.
    Stahl S (2008) Stahl’s essential psychopharmacology: neuroscientific basis and practical applications, 3rd edn. Cambridge University Press, New YorkGoogle Scholar
  19. 19.
    Nowell PD, Mazumdar S, Buysse DJ et al (1997) Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278:2170–2177PubMedCrossRefGoogle Scholar
  20. 20.
    Holbrook AM, Crowther R, Lotter A, Cheng C, King D (2000) Meta-analysis of benzodiazepine use in the treatment of insomnia. Canadian Medical Association Journal 162(2):225–233PubMedPubMedCentralGoogle Scholar
  21. 21.
    Walsh JK, Pollack CP, Scharf MB, Schweitzer PK, Vogel GW (2000) Lack of residual sedation following middle of the night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23(1):17–21PubMedCrossRefGoogle Scholar
  22. 22.
    Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26(7):793–799PubMedGoogle Scholar
  23. 23.
    Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T (2007) Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 30(8):959–968PubMedPubMedCentralGoogle Scholar
  24. 24.
    Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6(6):487–495PubMedCrossRefGoogle Scholar
  25. 25.
    Scharf MB, Roth T, Vogel GW, Walsh JK (1994) J Clin Psychiatry 55(5):192–199PubMedGoogle Scholar
  26. 26.
    Walsh JK, Vogel GW, Scharf M, Erman M, William EC, Schweitzer PK et al (2000) A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1(1):41–49PubMedCrossRefGoogle Scholar
  27. 27.
    Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS (2005) Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 6(2):107–113PubMedCrossRefGoogle Scholar
  28. 28.
    Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, Schweitzer PK (2000) Eight weeks of non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Sleep 23(8):1087–1096PubMedGoogle Scholar
  29. 29.
    Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65(8):1128–1137PubMedCrossRefGoogle Scholar
  30. 30.
    Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T (2008) ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31:79–90PubMedPubMedCentralGoogle Scholar
  31. 31.
    Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK (1999) Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60(10):68–76CrossRefGoogle Scholar
  32. 32.
    Fava M, Asnis G, Shrivastaava R, Lydiard RB, Bastani B, Sheehan D, Roth T (2008) Improved insomnia symptoms and daily functioning in patients wieth comorbid major depressive disorder and insomnia following zolpidem estended-release 12.5 mg and escitalopram co-treatment. Sleep 31:A324Google Scholar
  33. 33.
    Sheehan D, Asnis G, Shrivastava R, Lydiard RB, Bastani B, Roth T (2008) Zolpidem estended-release 12.5 mg co-adiministered with escitalopram improves insomnia symptoms and next-day functioning in generalized anxiety disorder comorbid with chronic insomnia. Sleep 31, A325Google Scholar
  34. 34.
    Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59(11):1052–1060PubMedCrossRefGoogle Scholar
  35. 35.
    Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and generalized anxiety disorder. Arch Gen Psychiatry 65(5):551–562PubMedCrossRefGoogle Scholar
  36. 36.
    Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK (1996) Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 23(2):245–252PubMedGoogle Scholar
  37. 37.
    Doghramji K, Browman CP, Gaddy JR, Walsh JK (1991) Triazolam diminishes daytime sleepiness and sleep fragmentation in patients with periodic limb movements in sleep. J Clin Psychopharmacol 11(5):284–290PubMedCrossRefGoogle Scholar
  38. 38.
    Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S (2003) Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood, and quality of life. Psychol Med 33(7):1223–1237PubMedCrossRefGoogle Scholar
  39. 39.
    McAndrews PM, Weiss RT, Sandor P, Taylor A, Carlen PL, Shapiro CM (2003) Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 18(1):51–57CrossRefGoogle Scholar
  40. 40.
    Blin O, Micallef-Roll J, Audebert C et al (2006) A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. J Clin Psychopharmacol 26:284–289PubMedCrossRefGoogle Scholar
  41. 41.
    Fairweather DB, Kerr JK, Hindmarch I (1992) The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eru J Clin Pharmacol 43:597–601CrossRefGoogle Scholar
  42. 42.
    Berlin I, Warot D, Hergueta T et al (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100–106PubMedCrossRefGoogle Scholar
  43. 43.
    Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8(4):309–325PubMedCrossRefGoogle Scholar
  44. 44.
    Kelly KD, Pickett W, Yiannakoulias N, Rowe BH, Schopflocher DP, Svenson L, Voaklander DC (2003) Medication use and falls in community-dwelling older persons. Age Ageing 32(5):503–509PubMedCrossRefGoogle Scholar
  45. 45.
    Brassington GS, King AC, Bliwise DL (2000) Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. J Am Geriatr Soc 48(10):1234–1240PubMedCrossRefGoogle Scholar
  46. 46.
    Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD (2005) Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53(6):955–962PubMedCrossRefGoogle Scholar
  47. 47.
    Roth T, Roehrs TA, Stepanski EJ et al (1990) Hypnotics and behavior. Am J Med 8:43S–46SCrossRefGoogle Scholar
  48. 48.
    Greenblatt D, Harmatz JS, Shapiro L et al (1991) Sensitivity to triazolam in elderly. N Engl J Med 324:1691–1698PubMedCrossRefGoogle Scholar
  49. 49.
    Buffett-Jerrott SE, Stewart SH (2002) Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8(1):45–58PubMedCrossRefGoogle Scholar
  50. 50.
    Roehrs T, Merlotti L, Zorick F, Roth T (1992) Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology (Berl) 108(1–2):67–71CrossRefGoogle Scholar
  51. 51.
    Griffiths RR, Roache JD (1985) Abuse liability of benzodiazepines: a review of human studies evaluating subjective and/or reinforcing effects. In: Smith DE, Wesson DR (eds) The benzodiazepines: current standards for medical practice. MTP, Hingman, MA, pp 209–225CrossRefGoogle Scholar
  52. 52.
    Balter MB, Uhlenhuth EH (1991) The beneficial and adverse effects of hypnotics. J Clin Psychiatry 52(7, suppl):16–23PubMedGoogle Scholar
  53. 53.
    Roehrs T, Bonahoom A, Pedrosi B et al (2002) Nighttime versus daytime hypnotic self-administration. Psychopharmacology 161:137–142PubMedCrossRefGoogle Scholar
  54. 54.
    Roehrs T, Pedrosi B, Rosenthal L, Roth T (1996) Hypnotic self administration and dose escalation. Psychopharmacology (Berl) 127(2):150–154CrossRefGoogle Scholar
  55. 55.
    Roehrs T, Bonahoom A, Pedrosi B et al (2002) Disturbed sleep predicts hypnotic self administration. Sleep Med 3:61–66PubMedCrossRefGoogle Scholar
  56. 56.
    Ladewig D (1983) Abuse of benzodiazepines in western European society–incidence and prevalence, motives, drug acquisition. Pharmacopsychiatria 16(4):103–106PubMedCrossRefGoogle Scholar
  57. 57.
    Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al (2005) Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48(2):301–310PubMedCrossRefGoogle Scholar
  58. 58.
    Erman M, Seiden D, Zammit G, Sainati S, Zheng J (2006) An efficacy, safety and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 7:17–24PubMedCrossRefGoogle Scholar
  59. 59.
    Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T (2007) Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 3:495–504PubMedPubMedCentralGoogle Scholar
  60. 60.
    Roth T, Seiden D, Sainati S, Wand-Weigand S, Zhang J, Zee P (2006) Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine 7(Wang-Weigand S, J):312–318PubMedCrossRefGoogle Scholar
  61. 61.
    Roth T, Seiden D, Wang-Weigand S, Zhang J (2007) A 2-night, 3-period crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23:1005–1014PubMedCrossRefGoogle Scholar
  62. 62.
    DeMicco M, Wang-Eeigand S, Zhang J (2006) Long-term therapeutic effects of ramelteon treatment in adults with chronic insomnia: a 1 year study. Sleep 29 (suppl):A234Google Scholar
  63. 63.
    Richardson G, Zammit G, Rodriguez L, Zhang J (2005) Evaluation of circadian phase-shifting effects of ramelteon in healthy subjects. In: Proceedings of international congress of applied chronobiology & chronomedicine, Antalya, Turkey, 1–5 June 2005Google Scholar
  64. 64.
    Borja NL, Daniel KL (2006) Ramelteon for the treatment of insomnia. Clin Ther 28:1540–1555PubMedCrossRefGoogle Scholar
  65. 65.
    Johnson MW, Suess P, Ramelteon GR (2006) A novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 63:1149–1157PubMedCrossRefGoogle Scholar
  66. 66.
    Brogden RN, Heel RC, Speight TM, Avery GS (1981) Trazodone: a review of its pharmacologic properties and therapeutic use in depression and anxiety. Drugs 21:401–429PubMedCrossRefGoogle Scholar
  67. 67.
    Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–229PubMedCrossRefGoogle Scholar
  68. 68.
    Frazer A (1997) Pharmacology of antidepressants. J Clin Psychopharmacol 17(Suppl 1):2S–18SPubMedCrossRefGoogle Scholar
  69. 69.
    Preskorn SH (1993) Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 54(Suppl):14–34PubMedGoogle Scholar
  70. 70.
    Richelson E (1994) The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 55(Suppl A):34–39PubMedGoogle Scholar
  71. 71.
    De Boer T (1996) The pharmacological profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19–25PubMedGoogle Scholar
  72. 72.
    Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O’Hanlon JF (2000) Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20(5):531–537PubMedCrossRefGoogle Scholar
  73. 73.
    Sharpley AL, Cowen PJ (1995) Effects of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37:85–98PubMedCrossRefGoogle Scholar
  74. 74.
    Mendelson WB (2005) A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 66:469–476PubMedCrossRefGoogle Scholar
  75. 75.
    Walsh JK, Erman M, Erwin CW, Jamieson A, Mahowald M, Regestein Q et al (1998) Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13:191–198CrossRefGoogle Scholar
  76. 76.
    Montgomery I, Oswald I, Morgan K, Adam K (1983) Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16:139–144PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C (2004) The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 5:15–20PubMedCrossRefGoogle Scholar
  78. 78.
    Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Ruther E et al (2002) Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 35:165–174PubMedCrossRefGoogle Scholar
  79. 79.
    Hohagen F, Montero RF, Weiss E, Lis S, Schonbrunn E, Dressing H et al (1994) Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 244(2):65–72PubMedCrossRefGoogle Scholar
  80. 80.
    Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F et al (2001) Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62:453–463PubMedCrossRefGoogle Scholar
  81. 81.
    Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30:1555–1561PubMedPubMedCentralGoogle Scholar
  82. 82.
    Roth T, Durrence H, Gotfried M, Hull S, Corser B, Scharf M, Orr W, Buddharaju V, Schwaretz H, Jochelson P (2008) Efficacy and safety of doxepin 1 and 3 mg in a 3-month trial of elderly adults with chronic primary insomnia. Sleep 31:A230Google Scholar
  83. 83.
    Gillin JC, Wyatt RJ, Fram D, Snyder F (1978) The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacol (Berl) 59:267–272CrossRefGoogle Scholar
  84. 84.
    Hartmann E, Cravens J (1973) The effects of long-term administration of psychotropic drugs on human sleep: III. The effects of amitriptyline. Psychopharmacologia 33:185–202PubMedCrossRefGoogle Scholar
  85. 85.
    Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, Weikel JC, Sonntag A, Steiger A (2006) Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine. Neuropsychopharmacology 31:832–844PubMedCrossRefGoogle Scholar
  86. 86.
    Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations: tricyclic antidepressants vs selective serotonin reuptake inhibitors. Acta Psychiatr Scand 101(Suppl 403):17–25CrossRefGoogle Scholar
  87. 87.
    Mir S, Taylor D (1997) The adverse effects of antidepressants [mood disorders]. Curr Opin Psychiatry 10(2):88–94CrossRefGoogle Scholar
  88. 88.
    Haria M, Fitton A, McTavish D (1994) Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4:331–355PubMedCrossRefGoogle Scholar
  89. 89.
    Golden RN, Dawkins K, Nicholas L (2004) Trazodone and nefazodone. In: Schatzberg A, Nemeroff CB (eds) The American Psychiatric Publishing Textbook of Psychopharmcaology. American Psychiatric Publishing, Washington DC, pp 315–325Google Scholar
  90. 90.
    Metz A, Shader RI (1990) Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 5:191–194PubMedCrossRefGoogle Scholar
  91. 91.
    Sakulsripong M, Curran HV, Lader M (1991) Does tolerance develop to the sedative and amnesic effects of antidepressants? A comparison of amitriptyline, trazodone and placebo. Eur J Clin Pharmacol 40:43–48PubMedCrossRefGoogle Scholar
  92. 92.
    Wiegand M, Landry T, Bruckner T, Pohl C, Zdenko V, Jahn T (2008) Quetiapine in primary insomnia: a pilot study. Psychopharmacology 196:337–338PubMedCrossRefGoogle Scholar
  93. 93.
    Juri C, Chana P, Tapia J, Kunstmann C, Parrao T (2005) Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial. Clin Neuropharmacol 28(4):185–187PubMedCrossRefGoogle Scholar
  94. 94.
    Estivill E, de la Fuente V, Segarra F, Albares J (2004) The use of olanzapine in sleep disorders. An open trial with nine patients. Rev Neurol 38(9):829–831PubMedGoogle Scholar
  95. 95.
    Rickels K, Morris RJ, Newman H, Rosenfeld H, Schiller H, Weinstock R (1983) Diphenhydramine in insomniac family practice patients: a double- blind study. J Clin Pharmacol 23(5–6):234–242PubMedCrossRefGoogle Scholar
  96. 96.
    Glass JR, Sproule BA, Herrmann N, Busto UE (2008) Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol 28:182–188PubMedCrossRefGoogle Scholar
  97. 97.
    Schweitzer PK, Muehlbach MJ, Walsh JK (1994) Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immuno 94:716–724CrossRefGoogle Scholar
  98. 98.
    Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T (2002) Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 22:511–515PubMedCrossRefGoogle Scholar
  99. 99.
    Basu R, Dodge H, Stoehr GP, Ganguli M (2003) Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J geriatric Psychiatry 11:205–213CrossRefGoogle Scholar
  100. 100.
    Hughes RJ, Badia P (1997) Sleep-promoting and hypothermic effects of daytime melatonin administration in human. Sleep 20:124–131PubMedGoogle Scholar
  101. 101.
    Dollins AB, Zhadnova IV, Wurtman RJ, Lynch HJ, Deng MH (1994) Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 91(5):1824–1828PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    James SP, Mendelson WB, Sack DA, Rosenthal NE, Wehr TA (1987) The effect of melatonin on normal sleep. Neuropsychopharmacology 1:41–44PubMedCrossRefGoogle Scholar
  103. 103.
    James SP, Sack DA, Rosenthal NE, Mendelson WB (1990) Melatonin administration in insomnia. Neuropsychopharmacology 3(1):19–23PubMedGoogle Scholar
  104. 104.
    MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL (1991) The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 20:371–376CrossRefGoogle Scholar
  105. 105.
    Lemoine P, Nir T, Laudon M, Zisapel N (2007) Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16:372–380PubMedCrossRefGoogle Scholar
  106. 106.
    Buscemi N, Vandermeer B, Hooton N et al (2005) The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 20:1151–1158PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Brzezinski A, Vangel MG, Wurtman RJ et al (2005) Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41–50PubMedCrossRefGoogle Scholar
  108. 108.
    Rogers NL, Kennaway DJ, Dawson D (2003) Neurobehavioral performance effects of daytime melatonin and temazepam administration. J Sleep Res 12:207–212PubMedCrossRefGoogle Scholar
  109. 109.
    Lusardi P, Preti P, Savino S, Piazza E, Zoppi A, Fogari R (1997) Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 2(2):99–103PubMedGoogle Scholar
  110. 110.
    Lusardi P, Piazza E, Fogari R (2000) Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 49(5):423–427PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Naylor S, Johnson KL, Williamson BL, Klarskov K, Gleich GJ (1999) Structural characterization of contaminants in commercial preparations of melatonin by on-line HPLC-electrospray ionization-tandem mass spectrometry. Adv Exp Med Biol 467:769–777PubMedCrossRefGoogle Scholar
  112. 112.
    Bliwise DL, Ansari FP (2007) Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 30(7):881–884PubMedPubMedCentralGoogle Scholar
  113. 113.
    Houighton PJ (1999) The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 51:505–512CrossRefGoogle Scholar
  114. 114.
    Krystal AD, Ressler I (2001) The use of valerian in neuropsychiatry. CNS Spectr 6:841–847PubMedCrossRefGoogle Scholar
  115. 115.
    Balderer G, Borbely AA (1985) Effect of valerian on human sleep. Psychopharmacology (Berl) 87(4):406–409CrossRefGoogle Scholar
  116. 116.
    Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I (2000) Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33(2):47–53PubMedCrossRefGoogle Scholar
  117. 117.
    Schulz H, Stolz C, Muller J (1994) The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 27(4):147–151PubMedCrossRefGoogle Scholar
  118. 118.
    Morin CM, Koetter U, Bastien C, Ware JC, Wooten V (2005) Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 28(11):1465–1471PubMedGoogle Scholar
  119. 119.
    Stevinson C, Ernst E (2000) Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 1(2):91–99PubMedCrossRefGoogle Scholar
  120. 120.
    Taibi DM, Landis CA, Petry H, Vitiello MV (2007) A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 11(3):209–230PubMedCrossRefGoogle Scholar
  121. 121.
    Chouinard G, Lefko-Singh K, Teboul E (1999) Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 19(4):533–552PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Paula K. Schweitzer
    • 1
  • Denise Troy Curry
    • 1
  • Rhody D. Eisenstein
    • 1
  • James K. Walsh
    • 1
  1. 1.Sleep Medicine and Research CenterSt. Luke’s HospitalChesterfieldUSA

Personalised recommendations